We aimed to investigate the effects of zoledronic acid treatment on daily living activities, cognitive functions, depression, muscle strength, and performance.
The study was conducted retrospectively. Bone mineral densitometry (BMD) values, Katz activities of daily living (ADL), Lawton-Brody instrumental activities of daily living (IADL), mini mental state examination (MMSE), geriatric depression scale (GDS), mini nutritional assessment (MNA), grip strength, and gait speed scores before and 6 months after zoledronic acid administration were compared.
A total of 115 patients were included in the study. There was a significant increase in lumbar total (p < .001), femoral neck (p = .002), and femur total (p = .001) BMD values after zoledronic acid treatment. Significant decrease was found in MMSE (p = .016) and gait speed scores (p = .008) after zoledronic acid treatment, but no significant difference was found in terms of Katz ADL, Lawton-Brody IADL, MNA, GDS, and grip strength (p > .05).
Our study indicated that zoledronic acid did not affect daily living activities, depression, and muscle strength. Although we have concluded that cognitive and muscle performance may be adversely affected by zoledronic acid treatment.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Bhansali A (2012) Metabolic bone disease: newer perspectives. Indian J Endocrinol Metab 16(Suppl 2):S140–S141
Maclaughlin EJ, Sleeper RB, McNatty D et al (2006) Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag 2(3):281–295
Zadeh AF, Hanafi MG, Kiasat A, Mousavi M (2019) Evaluation of the tibial cortical thickness accuracy in osteoporosis diagnosis in comparison with dual energy X-ray absorptiometry. J Family Med Prim Care 8(2):523–527
U.S. Preventive Services Task Force (2011) Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 154(5):356–364
Lewiecki EM (2010) Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis 1(3):115–128
Mottaghi P (2010) Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci. 15(3):175–184
Pazianas M, Abrahamsen B, Ferrari S, Russell RG (2013) Eliminating the need for fasting with oral administration of bisphosphonates. Ther Clin Risk Manag 9:395–402
Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT (2010) Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosismanagement. Drug Healthc Patient Saf 2:121–137
Dilek B, Şahin E, Erdem D, et al. (2017) Patient satisfaction, preference and side effects after annual zoledronic acid infusion in patients with osteoporosis 23(1): 21–25
Liu M, Guo L, Pei Y, Li N, Jin M, Ma L, Liu Y, Sun B, Li C (2015) Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis. Int J Clin Exp Med 8(3):3855–3861
Wang C (2017) Efficacy and safety of zoledronic acid for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials. Am J Ther 24(5):e544–e552
Devogelaer JP, Brown JP, Burckhardt P, Meunier PJ, Goemaere S, Lippuner K, Body JJ, Samsioe G, Felsenberg D, Fashola T, Sanna L, Ortmann CE, Trechsel U, Krasnow J, Eriksen EF, Garnero P (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18(9):1211–1218
Hsieh PC (2016) Effectiveness and safety of zoledronic acid in the treatment of osteoporosis. Orthopedics. 39(2):e263–e270
Kotian P, Boloor A, Sreenivasan S (2016) Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis. J Clin Diagn Res 10(1):OC04–OC06
Wark JD, Bensen W, Recknor C, Ryabitseva O, Chiodo J, Mesenbrink P, de Villiers TJ (2012) Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int 23(2):503–512
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809
Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367(18):1714–1723
Tasci I, Safer U, Cintosun U, Bozoglu E, Naharci I, Aydogdu A, Meric C, Doruk H (2016) Zoledronic acid use and risk of cognitive decline among elderly women and men with osteoporosis. Endocr Metab Immune Disord Drug Targets 16(1):32–38
Gokosmanoglu F, Varim C, Atmaca A et al (2016) The effects of zoledronic acid treatment on depression and quality of life in women with postmenopausal osteoporosis: a clinical trial study. J Res Med Sci 21:112
Arik G, Varan HD, Yavuz BB, Karabulut E, Kara O, Kilic MK, Kizilarslanoglu MC, Sumer F, Kuyumcu ME, Yesil Y, Halil M, Cankurtaran M (2015) Validation of Katz index of independence in activities of daily living in Turkish older adults. Arch Gerontol Geriatr 61(3):344–350
Hopkins RO, Suchyta MR, Kamdar BB, Darowski E, Jackson JC, Needham DM (2017) Instrumental activities of daily living after critical illness: a systematic review. Ann Am Thorac Soc 14(8):1332–1343
Goudsmit M, van Campen J, Schilt T, Hinnen C, Franzen S, Schmand B (2018) One size does not fit all: comparative diagnostic accuracy of the rowland universal dementia assessment scale and the mini mental state examination in a memory clinic population with very low education. Dement Geriatr Cogn Dis Extra 8(2):290–305
Durmaz B, Soysal P, Ellidokuz H, Isik AT (2018) Validity and reliability of geriatric depression scale-15 (short form) in Turkish older adults. North Clin Istanb 5(3):216–220
Sarikaya D, Halil M, Kuyumcu ME, Kilic MK, Yesil Y, Kara O, Ozturk S, Gungor E, Karabulut E, Balam Yavuz B, Cankurtaran M, Ariogul S (2015) Mini nutritional assessment test long and short form are valid screening tools in Turkish older adults. Arch Gerontol Geriatr 61(1):56–60
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2, Bautmans I, Baeyens JP, Cesari M, Cherubini A, Kanis J, Maggio M, Martin F, Michel JP, Pitkala K, Reginster JY, Rizzoli R, Sánchez-Rodríguez D, Schols J (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31
Satoh T, Kimura M, Matsumoto K, Tabata KI, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer. 115(15):3468–3474
Sunyecz JA (2010) Zoledronic acid infusion for prevention and treatment of osteoporosis. Int J Women's Health 2:353–360
Nasiruddin M, Fayazuddin M, Zahid M et al (2014) Acute delirium in an elderly woman following zoledronate administration. J Pharmacol Pharmacother 5(3):217–219
Safer U, Safer VB, Demir SO et al (2016) Effects of bisphosphonates and calcium plus vitamin-D supplements on cognitive function in postmenopausal osteoporosis§. Endocr Metab Immune Disord Drug Targets 16(1):56–60
Tow A, Holtzer R, Wang C, Sharan A, Kim SJ, Gladstein A, Blum Y, Verghese J (2016) Cognitive reserve and postoperative delirium in older adults. J Am Geriatr Soc 64(6):1341–1346
Zameer S, Najmi AK, Vohora D, Akhtar M (2018) Bisphosphonates: future perspective for neurological disorders. Pharmacol Rep 70(5):900–907
Gong L, Altman RB, Klein TE (2011) Bisphosphonates pathway. Pharmacogenet Genomics 21(1):50–53
Schultz BG, Patten DK, Berlau DJ (2018) The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener 7:5
Orth M, Bellosta S (2012) Cholesterol: its regulation and role in central nervous system disorders. Cholesterol. 2012:292598
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bahşi, R., Atmiş, V., Turgut, T. et al. May zoledronic acid have negative effects on cognition and muscle performance?. Ir J Med Sci 189, 191–196 (2020). https://doi.org/10.1007/s11845-019-02086-5
- Cognitive function
- Gait speed
- Zoledronic acid